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date. This study provides an estimate of the cost-effectiveness of
memantine compared with standard care (no pharmacotherapy)
in moderate to severe AD adapted to a Canadian setting and
including all available evidence. No other pharmacological treat-
ment was included in the evaluation as memantine is currently
the only drug approved in this indication. METHODS: The pro-
gression of AD in terms of cognitive severity, functional dis-
ability and mortality was simulated over two-years using a 
state-transition (Markov) model. Outcomes of the model were
Quality-Adjusted Life-Years (QALY) and costs from a societal
perspective. The main cost and epidemiological input parame-
ters of the model were computed using data from the Canadian
Study on Health and Aging (CSHA). All relevant published and
unpublished clinical trials of memantine versus placebo in mod-
erate to severe AD were used to compute the transition proba-
bilities between health states. A priori distributions were
associated to all relevant parameters in order to enable stochas-
tic analyses. RESULTS: Compared with standard care, the
memantine strategy produced 0.03 additional QALYs, with no
additional overall cost. Probabilistic sensitivity analyses give
83.3% chance that memantine treatment is cost neutral, 89.5%
chance of being cost-effective if the decision-maker is willing to
pay $20,000 for a quality-adjusted life year and 96.2% chance
for a willingness-to-pay of $100,000 per QALY. Robustness of
the results was conﬁrmed through one-way and scenario-based
sensitivity analyses. CONCLUSIONS: Our evaluation found
memantine dominant over standard care. Results were compa-
rable with those published for acetylcholinesterase inhibitors
indicated for treatment of earlier stages of AD.
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OBJECTIVE: To determine cost-effectiveness of antidepressant
groups (SNRIs, SSRIs, and TCAs) in treating major depressive
disorder (MDD) over a 6-month time horizon from the view-
point of the Brazilian Ministry of Health. METHODS: An exist-
ing decision tree model developed by our group was adapted to
Brazil, based on Brazilian treatment guidelines. Clinical data
were obtained from a published meta-analysis of remission rates
published by Machado et al. Patients included adults >= 18 with
MDD, diagnosed using DSM-III/IV or comparable, with moder-
ate-to-severe disease (HAMD >= 15 or MADRS >= 18), without
comorbidities or comedications, and followed by >= 6 weeks of
treatment. Treatments included: SNRIs (venlafaxine, duloxetine,
milnacipran), SSRIs (citalopram, escitalopram, ﬂuoxetine,
paroxetine, sertraline) and/or TCAs (clomipramine, amitripty-
line, nortriptyline, imipramine). SSRIs were used as secondary
treatment for SNRIs and TCAs, TCAs were used as secondary
treatment for SSRIs. Clinical outcome was remission, deﬁned as
a ﬁnal HAMD score <= 7 or MADRS <= 12. Included were all
direct costs of treatment (drug, physician visits, hospitalization).
Drug costs were obtained from the 2006 Brazilian National Drug
Price List. Costs of hospitalizations and physician visits were
taken from the 2006 Health care System database (DATASUS).
All costs were presented in undiscounted 2006 Brazilian Reais
(1R$ = USD$0.46). Univariate and Monte Carlo sensitivity
analyses were performed. RESULTS: The primary ITT remission
rate of SNRIs was signiﬁcantly (P < 0.05) higher than SSRIs and
TCAs. Expected costs/patient treated were: SNRIs = R$4698;
SSRIs = R$5341; TCAs = R$4867. Overall success rates (primary
+ secondary treatment across all decision tree branches) were:
SNRIs = 78.1%; SSRIs = 74.0%; TCAs = 76.4%. Average
costs/success were: SNRIs = R$6017; SSRIs = R$7217; TCAs =
$6368. Monte Carlo analysis conﬁrmed the relative positions.
Break-even analysis showed that results were sensitive to varia-
tions to primary success rates. CONCLUSIONS: SNRIs domi-
nated the other two antidepressant classes. Using SNRIs on
average could save the government R$775 million annually.
Further analyses are warranted to conﬁrm results since they were
sensitive to primary remission rates.
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OBJECTIVES: Economic models have demonstrated the cost-
effectiveness of escitalopram versus citalopram in major depres-
sive disorder (MDD), but no head-to-head clinical trials have
evaluated their cost-effectiveness to date. The objective of this
study was to assess the relative cost-effectiveness of escitalopram
compared with citalopram in outpatients with MDD.
METHODS: An economic evaluation was conducted alongside
a double-blind randomized clinical trial conducted by French
general practitioners and psychiatrists, comparing ﬁxed doses of
escitalopram (20 mg/day) or citalopram (40 mg/day) over 8
weeks in outpatients with MDD (baseline Montgomery-Åsberg
Depression Rating Scale (MADRS) score ≥30). A standardised
health care services form was used to record physician visits, hos-
pitalisations, treatments and days of sick leaves for the 2-month
pre-study period and the 8-week study period. RESULTS: Sta-
tistically signiﬁcant improvements in remission rates were
observed in patients treated with escitalopram (56% vs. 43%, 
p < 0.05). Using the price of the generic citalopram, mean per-
patient costs from a health care perspective for the escitalopram
group were 45% lower than the citalopram group (€79 vs. €144;
p < 0.05). Differences were mostly related to lower hospitalisa-
tion costs. Bootstrapped distributions of the cost-effectiveness
ratios also showed better effectiveness and lower costs for esci-
talopram compared with citalopram with more than 85% of 
the draws located in the southeastern quadrant of the cost-
effectiveness plan, indicating that escitalopram was the dominant
strategy. Sensitivity analyses conﬁrmed the dominance of esci-
talopram over citalopram from a payer perspective. CONCLU-
SIONS: Escitalopram is signiﬁcantly more effective than
citalopram and is associated with lower health care costs. This
prospective economic analysis demonstrated that escitalopram is
a cost-effective ﬁrst-line treatment option for MDD.
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OBJECTIVES: Despite progress in the treatment of schizophre-
nia following the introduction of atypical antipsychotics in the
late 1990s, current pharmacological options still carry limita-
tions, as highlighted in a recent, pragmatic study in the US.
Sertindole is an atypical antipsychotic with a good tolerability
proﬁle likely to favour long-term adherence, reductions in
relapse and re-hospitalisation rates, and improvements in overall
